IMEXHS Faces Political Risks Despite Radiology Services Turnaround and AI Advances

Financial Milestones and Profitability Turnaround

IMEXHS Limited (ASX:IME) delivered a strong financial performance in FY25, posting $29 million in revenue, a 10% increase year-on-year, and underlying EBITDA of $1.6 million, more than tripling the prior year’s $0.5 million. The company ended the year with $3.3 million in cash and reduced debt to $0.5 million, underscoring improved financial discipline and operational efficiency. This performance came in at the top end of management’s guidance, reflecting deliberate efforts to tighten credit terms and exit underperforming contracts.

By segment, the software division grew revenue by 12% with a 19% increase in Annual Recurring Revenue (ARR) to $11.8 million and maintained a robust 30% EBITDA margin. Meanwhile, the radiology services arm, RIMAB, reversed previous losses to achieve a 7% EBITDA margin through contract renegotiations, pricing discipline, and AI-driven automation. This turnaround was a major factor in the company’s improved profitability, with RIMAB now contributing positive cash flow after years of inflationary pressure challenges.

The momentum carried into Q1 FY26, with revenue rising 13% to $7.9 million and underlying EBITDA jumping to $0.8 million from $0.1 million in the prior corresponding period. The software partner programme accounted for 60% of new software ARR during the quarter, validating IMEXHS’s channel strategy across Latin America. Notable contract wins included CESAC IPS in Cartagena and Hospital La Misericordia, reflecting expanding geographic reach and partner engagement. This builds on the company’s earlier success with contracts such as Salud Total Group in Colombia and Hospital Neurológico de México, which collectively added significant ARR in FY25 Q1 FY26 revenue rises 13%.

Aquila+ Platform and Proprietary AI Agents

Central to IMEXHS’s growth story is its cloud-native Aquila+ platform, which now supports 566 installations across 18 countries. The platform’s development continued on time and budget, with capital costs decreasing over the past three years. Aquila+ boasts ISO 27001 certified security, rapid remote deployment, integrated AI, and scalability for large hospital groups. Its fully cloud-based architecture delivers the lowest total cost of ownership for customers and operational efficiencies for IMEXHS.

IMEXHS has embedded five proprietary AI agents into Aquila+, automating the entire radiology workflow from appointment scheduling to final report delivery. These agents include Intelligent Appointment Scheduling, Study Prioritisation, Auto-Distribution, Non-Attendance Alerts, and RV Mentor, an AI co-pilot for radiologists. Two agents are live, one is in final testing, and two are under active development. This comprehensive AI integration addresses operational bottlenecks beyond image interpretation, a gap largely unfilled by competitors. The agents are already contributing materially to RIMAB’s improved performance and are being rolled out to software clients, enhancing client dependency and increasing switching costs.

Strategic Expansion and Market Dynamics

IMEXHS’s partner programme matured into a functioning distribution engine, with 27 active partners across 12 countries delivering 46 partner-led deals in FY25. This channel expansion underpins the company’s ambition to accelerate software growth. Key contract wins such as the Oncolife oncology radiology deal in Colombia, which grew from an expected $1.4 million to $2.1 million in ARR, illustrate the synergy of combining high-complexity services with software and AI layers Oncolife contract in Colombia.

However, IMEXHS continues to navigate a challenging political and economic environment in Latin America. Colombia’s healthcare payment system remains under pressure ahead of presidential elections, while Venezuela’s deteriorated healthcare infrastructure presents both risks and potential future opportunities as the country seeks recovery. The company maintains contingency plans and working capital discipline to manage these uncertainties.

Leadership and Forward-Looking Priorities

Leadership transitions include the appointment of a new CTO, Sales Director, and COO Daniel Laverde, bringing experience from Mercado Libre and Blackboard. This team is focused on scaling the AI-native operating system for radiology, aiming to reduce costs, improve clinical outcomes, and enable volume growth without proportional headcount increases.

IMEXHS’s FY26 guidance targets exceeding FY25 underlying EBITDA, achieving full-year cash positivity, and accelerating software revenue growth. The company plans to continue deploying AI agents, strengthen its partner channel, grow radiology services opportunistically, and expand margins through automation and portfolio mix. More detailed guidance will be provided at the H1 results in August 2026. Early Q1 results suggest the company is on track to meet these goals IMEXHS Accelerates AI Radiology.